Detail akcie CureVac Rg online

Business Summary: CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Financial Summary: BRIEF: For the three months ended 31 March 2025, CureVac BV revenues decreased 93% to EUR893K. Net loss decreased 26% to EUR52.1M. Revenues reflect Belgium (Country) segment decrease of 97% to EUR306K, Switzerland segment decrease of 83% to EUR586K. Lower net loss reflects General and administrative expenses decrease of 16% to EUR9M (expense), salary and salary-related expenses decrease of 17% to EUR4.9M (expense).